Stay updated with breaking news from Term Safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tolebrutinib is an Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a long-term extension study of the phase 2b dose-finding trial.
Two-year data on magnetic resonance imaging (MRI), efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.
– Pivotal Phase III data will be spotlighted via an oral presentation – – Additional efficacy and safety data will be featured across four posters – ... | June 18, 2023
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American...
Cognitive behavioral therapy should be the first-line therapy for insomnia in seniors, but many clinicians are unaware of its benefits, experts say.